FDL Clinical Studies

FDL169 a CFTR Corrector

FDL169 is an oral drug that improves the function of the protein that’s defective in Cystic Fibrosis (CF) (the CFTR protein), a type of compound known as a CFTR corrector. FDL169 is planned as long-term treatment of CF. In laboratory tests, FDL169 has been shown to increase the movement of chloride and the amount of the defective CFTR protein on the surface of the cells that line the bronchial tubes.

FDL176 a CFTR Potentiator

FDL176 is an oral drug that improves the function of the protein that’s defective in Cystic Fibrosis (CF) (the CFTR protein), a type of compound known as a CFTR potentiator. FDL176 is planned as long-term treatment of CF. In laboratory tests, FDL176 has been shown to increase the movement of chloride across CFTR protein that is present on the surface of the cells that line the bronchial tubes after treatment with a CFTR corrector.

Have an Idea?

We’d love to hear it!

Submit an Idea